According to the 2016 CHEST VTE Guidelines, at least 3 months of therapy is recommended for an unprovoked DVT or PE (Grade 1B). Thereafter, the clinician is expected to weigh the risks and benefits to determine if extended therapy is appropriate. Balancing the risk of mortality from recurrent VTE versus major bleeding has been challenging. A validated clinical decision tool is sorely needed! Until recently, no risk assessment tool has been validated and therefore none have been widely adopted in practice.
Guest Author: Carol Chan, Pharm.D.
Music by Good Talk